首页|生物制剂诱发葡萄膜炎的研究进展

生物制剂诱发葡萄膜炎的研究进展

Research Progress on Biologic Agents Inducing Uveitis

扫码查看
生物制剂诱发葡萄膜炎的案例近年来多有报道.本文对生物制剂诱发葡萄膜炎的文献进行系统回顾并总结临床特点,发现目前引起葡萄膜炎的生物制剂主要包括5类,即肿瘤坏死因子-α(TNF-α)抑制剂、抗血管内皮生长因子(VEGF)、免疫检查点抑制剂、B-Raf原癌基因(BRAF)-丝裂原活化蛋白激酶(MEK)抑制剂和注射疫苗,多用于治疗类风湿性关节炎、肿瘤、强直性脊柱炎、眼内炎等疾病,患者年龄区间为1个月~92岁,发作时间为用药后1 d~6年不等.当前有限的证据显示,TNF-α抑制剂更易诱发葡萄膜炎的发生.生物制剂诱发葡萄膜炎类型以前葡萄膜炎为主,且存在复发倾向.经糖皮质激素、散瞳治疗,停止生物制剂使用后,绝大多数的诱发性葡萄膜炎患者的视力预后较好.
There have been numerous reports in recent years regarding uveitis induced by biologic agents.This paper systematically reviews the literature on uveitis induced by biologic agents and summarizes the clinical characteristics.It is found that the biologic agents currently causing uveitis mainly include five categories:Tumor necrosis factor-α(TNF-α)inhibitors,anti-vascular endothelial growth factor(VEGF)agents,immune checkpoint inhibitors,B-Raf proto-oncogene(BRAF)and mitogen-activated protein kinase(MEK)inhibitors,and injectable vaccines.These agents are commonly used to treat conditions such as rheumatoid arthritis,tumors,ankylos-ing spondylitis,uveitis,among others,with patients ranging in age from one month to 92 years and onset times varying from one day to six years post-medication.Current limited evidence suggests that TNF-α inhibitors are more prone to inducing uveitis.The type of uveitis induced by biologic agents is mainly anterior uveitis,and there is a tendency for recurrence.With steroid and mydri-atic treatment and cessation of biologic agent use,the visual prognosis of most patients with in-duced uveitis is good.

biologic agentsuveitistumor necrosis factor-αside effects

孙武、茹姝婷、史航、陈水龄、吴建国、韦东、褚利群

展开 >

中国中医科学院西苑医院,北京 100091

生物制剂 葡萄膜炎 肿瘤坏死因子-α 副作用

中国中医科学院科技创新工程针灸临床学科重大攻关项目中国中医科学院自主选题项目

C12021A03513ZZ16-XRZ-024

2024

中国中医眼科杂志
中国中医科学院

中国中医眼科杂志

CSTPCD
影响因子:0.476
ISSN:1002-4379
年,卷(期):2024.34(5)
  • 38